Pertuzuamab administration can result in subclinical and clinical cardiac failure. Evaluate left ventricular function in all patients prior to and during treatment with Pertuzuamab. Discontinue Pertuzuamab treatment for a confirmed clinically significant decrease in left ventricular function.
Embryo-Fetal Toxicity
Exposure to Pertuzuamab can result in embryo-fetal death and birth defects. Studies in animals have resulted in oligohydramnios, delayed renal development, and death. Advise patients of these risks and the need for effective contraception.